| First Author | Lapierre JA | Year | 2022 |
| Journal | Biochem Biophys Res Commun | Volume | 634 |
| Pages | 100-107 | PubMed ID | 36242915 |
| Mgi Jnum | J:330340 | Mgi Id | MGI:7378009 |
| Doi | 10.1016/j.bbrc.2022.10.016 | Citation | Lapierre JA, et al. (2022) Deletion of monoamine oxidase A in a prostate cancer model enhances anti-tumor immunity through reduced immune suppression. Biochem Biophys Res Commun 634:100-107 |
| abstractText | We have previously shown that monoamine oxidase A (MAO A) mediates prostate cancer growth and metastasis. Further, MAO A/Pten double knockout (DKO) mice were generated and demonstrated that the deletion of MAO A delayed prostate tumor development in the Pten knockout mouse model of prostate adenocarcinoma. Here, we investigated its effect on immune cells in the tumor microenvironment in MAO A/Pten DKO mouse model. Our results shows that Paraffin embedded prostate tissues from MAO A/Pten DKO mice had elevated markers of immune stimulation (CD8(+) cytotoxic T cells, granzyme B, and IFNgamma) and decreased expression of markers of immune suppression (FoxP3, CD11b, HIF-1-alpha, and arginase 1) compared to parental Pten knockouts (MAO A wildtype). CD11b(+) myeloid derived suppressor cells (MDSC) were the primary immunosuppressive cell types in these tumors. The data suggest that deletion of MAO A reduces immune suppression in prostate tumors to enhance antitumor immunity in prostate cancer. Thus, MAO A inhibitor may alleviate immune suppression, increase the antitumor immune response and be used for cancer immunotherapy. |
